FSD Pharma at the H.C. Wainwright 2nd Annual Psychedelics TORONTO--(
BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“
FSD Pharma” or the “
Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright 2
nd Annual Virtual Psychedelics Conference to be held on December 6, 2021. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET and accessible to view on the investor relations section of FSD’s website at
https://ir.fsdpharma.com/news-events/events-presentations.
In addition, members of FSD Pharma’s management team will be available for one-on-one investor meetings during the conference.
For more information about the conference, or to schedule a one-on-one meeting with FSD's management team, please contact KCSA Strategic Communications at
FSDPharma@kcsa.com or an H.C. Wainwright representative directly.
About FSD Pharma FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (“FSD BioSciences”) is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Through the Company’s wholly owned subsidiary, Lucid, the Company is also focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
Contacts Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc.
Email:
Zsaeed@fsdpharma.com Telephone: (416) 854-8888
Investor Relations: Email:
skilmer@fsdpharma.com, Website:
www.fsdpharma.com